Albany Molecular Research (AMRI) Tops Q2 EPS by 4c; Updates FY16 Expectations

Albany Molecular Research (NASDAQ: AMRI) reported Q2 EPS of $0.36, $0.04 better than the analyst estimate of $0.32. Revenue for the quarter came in at $116.5 million versus the consensus estimate of $123.1 million.

GUIDANCE:

Albany Molecular Research sees FY2016 EPS of $1.03-$1.11, versus the consensus of $1.05. Albany Molecular Research sees FY2016 revenue of $590-615 million, versus the consensus of $522.5 million.

For earnings history and earnings-related data on Albany Molecular Research (AMRI) click here.

You May Also Be Interested In

• Toll Brothers (TOL) Tops Q3 EPS by 5c, reaffirms guidance
• Taylor Devices (TAYD) Misses Q4 EPS by 31c
• Iridex Corp (IRIX) Misses Q2 EPS by 5c